Inactive Instrument

All News Zeltia SA

Equities

ES0184940817

End-of-day quote BME Other stock markets
- ^EUR	-

2015	Alibaba's Singles' Day sales surge 60 percent to $14.3 billion	RE
2015	Alibaba : China consumers to spend more in November 11 'Singles Day' shopping spree - Nielsen	RE

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Alibaba's Singles' Day sales surge 60 percent to $14.3 billion	11/15/11	RE
Alibaba : China consumers to spend more in November 11 'Singles Day' shopping spree - Nielsen	04/15/04	RE
Zeltia : PharmaMar to Present New Studies for YONDELIS® and PM1183 in Ovarian Cancer during ESGO 2015	26/15/26	PU
Zeltia : U.S. FDA Approves YONDELIS® (trabectedin) for Soft Tissue Sarcoma (Liposarcoma or Leiomyosarcoma)	23/15/23	PU
Zeltia : Grupo Zeltia reports 126.8 million euro in net sales (+8.5%) in the first nine months of 2015	21/15/21	PU
Zeltia : Enrollment of first patient in a Phase II trabectedin study in brain tumor type called meningioma	21/15/21	PU
Zeltia : PharmaMar initiates a phase II “Basket” trial for PM1183 in selected advanced solid tumors	17/15/17	PU
Zeltia : PharmaMar opens new affiliate in UK	15/15/15	PU
Zeltia : Pharmaceutical Council Recommends Approval of YONDELIS® (trabectedin) in Japan	01/15/01	PU
Zeltia : PharmaMar announces license agreement with Specialised Therapeutics Australia Pty for APLIDIN® (plitidepsin) in oncology	20/15/20	PU
Zeltia : PharmaMar passes the U.S. FDA manufacturing inspection for YONDELIS® active ingredient	31/15/31	PU
Zeltia : Grupo Zeltia Reports First Half 2015 Financial Results	28/15/28	PU
Zeltia : PharmaMar announces license agreement with TTY Biopharm for APLIDIN® (plitidepsin) in hematological cancers	23/15/23	PU
Zeltia : GENOMICA and the Foundation for Excellence and Quality in Oncology announce a framework agreement for collaboration in Oncology	22/15/22	PU
Zeltia : PharmaMar initiates the phase III study CORAIL for the anticancer agent PM1183 in patients with platinum-resistant ovarian cancer	29/15/29	PU
Zeltia : PharmaMar announces that Janssen´s study shows that trabectedin improves disease control in patients with advanced soft tissue sarcoma	02/15/02	PU
Zeltia : PharmaMar completes patient recruitment of Phase III registration trial (ADMYRE) with APLIDIN® (plitidepsin) in multiple myeloma	01/15/01	PU
Zeltia : PharmaMar finaliza el reclutamiento de pacientes del ensayo de Fase III de registro (ADMYRE) con APLIDIN® (plitidepsin) en mieloma múltiple	01/15/01	PU
Zeltia : Grupo Zeltia Reports First Quarter 2015 Financial Results	27/15/27	PU
Zeltia : PharmaMar to present data on anticancer candidates PM1183 and plitidepsin at the AACR Annual Meeting 2015	14/15/14	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Zeltia SA

Equities

ES0184940817

All News

Filters